NO. 4 THE FORUM, ST. HELIER, Y9
Reports First Quarter 2026 Financial Results
Amended material disclosure
Chief Medical Officer Assignment
Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
CMS Rescinds Billing Privileges Revocation for Novocure Inc.
FDA Approves Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Reg. FD
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS